Head-to-head

Semaglutide vs AOD-9604

A field-by-field comparison of Semaglutide and AOD-9604 drawn from the PeptideIndex database: mechanism, evidence grade, half-life, administration route, reported dosing, side effects, storage and legal status. Both are indexed as metabolic compounds, so the useful question is how they differ within that category.

Semaglutide vs AOD-9604: editorial summary

Semaglutide and AOD-9604 are both discussed in the context of weight and fat metabolism, but their evidence and mechanisms are very different. Semaglutide is a clinically established GLP-1 receptor agonist, while AOD-9604 is a fragment of human growth hormone studied for effects on fat metabolism.

Key considerations

Semaglutide has Strong evidence and regulatory approvals, with clinical trials demonstrating substantial effects on body weight and glucose-related outcomes. AOD-9604 has a Limited evidence grade in the PeptideIndex database, and its profile specifically notes that phase IIb trials failed to outperform placebo for weight loss at 12 weeks.
This makes the evidence distinction particularly important. AOD-9604's proposed mechanism is focused on lipolysis and inhibition of lipogenesis without activating the conventional GH receptor, whereas semaglutide acts through GLP-1 signalling.

Semaglutide characteristics

Semaglutide is a long-acting GLP-1 analogue with extensive clinical evidence and approved prescription indications.

AOD-9604 characteristics

AOD-9604 is a fragment corresponding to the 176–191 region of human growth hormone. PeptideIndex rates its evidence Limited and notes underwhelming weight-loss trial results.

Semaglutide vs AOD-9604 at a glance

Attribute	Semaglutide	AOD-9604
Category	Metabolic	Metabolic
Evidence grade	Strong	Limited
Also known as	Ozempic, Wegovy	Anti-Obesity Drug 9604, hGH fragment 176-191
Chain	GLP-1 analogue, 94% homology to human GLP-1	Fragment 176-191 of human growth hormone
Mechanism	Mimics GLP-1 to enhance glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying and act on hypothalamic appetite centres. Fatty-acid acylation extends its half-life to once-weekly dosing.	Represents the lipolytic C-terminal region of hGH. In adipocytes it stimulates lipolysis and inhibits lipogenesis without binding the GH receptor, so IGF-1 and glucose remain unaffected.
Reported benefits	~15% mean body-weight reduction over 68 weeks in STEP-1 · Improved HbA1c and cardiovascular outcomes · Marked reduction in appetite and food noise	Fat mobilisation without IGF-1 elevation · No reported impact on insulin sensitivity · Good tolerability profile in trials
Reported side effects	Nausea and vomiting · Constipation or diarrhoea · Gallbladder issues · Contraindicated with medullary thyroid carcinoma history	Generally well tolerated · Occasional injection-site reaction · Headache
Half-life	About 7 days	Under 30 minutes
Administration	Once-weekly subcutaneous injection (oral tablet also approved)	Subcutaneous injection, often fasted in the morning
Dosing overview	Label titration from 0.25 mg weekly up to 2.4 mg over 16+ weeks	Commonly cited at 300 mcg daily, 5 days on / 2 off
Storage	Refrigerate 2–8 °C; in-use pens may be kept at room temperature per label	Refrigerate reconstituted vials; powder stable at room temperature briefly
Legal status	FDA-approved and prescription-only.	Not approved as a drug; permitted as a food additive in some jurisdictions.

Key differences between Semaglutide and AOD-9604

Both are metabolic compounds

Semaglutide and AOD-9604 are both indexed under metabolic, so they compete for the same use case rather than complementing each other. Semaglutide: "A long-acting GLP-1 receptor agonist with the strongest clinical weight-loss evidence of any peptide on the market." AOD-9604: "A GH fragment marketed for fat loss without the blood-sugar effects of full growth hormone — though human trials have been underwhelming."

Mechanism of action

Semaglutide: Mimics GLP-1 to enhance glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying and act on hypothalamic appetite centres. Fatty-acid acylation extends its half-life to once-weekly dosing. AOD-9604: Represents the lipolytic C-terminal region of hGH. In adipocytes it stimulates lipolysis and inhibits lipogenesis without binding the GH receptor, so IGF-1 and glucose remain unaffected.

Evidence quality is not equal

Semaglutide carries a Strong evidence grade and AOD-9604 a Limited grade on this index. The grade describes the quality of published human data, not how well a compound works — Semaglutide has the better-documented record of the two, and claims made about AOD-9604 rest on thinner human evidence.

Half-life and dosing frequency

Semaglutide is listed at about 7 days; AOD-9604 at under 30 minutes. That difference is what drives the reported schedules: Label titration from 0.25 mg weekly up to 2.4 mg over 16+ weeks versus Commonly cited at 300 mcg daily, 5 days on / 2 off

Route of administration

Semaglutide is administered by once-weekly subcutaneous injection (oral tablet also approved). AOD-9604 is administered by subcutaneous injection, often fasted in the morning.

Legal and regulatory status differs

Semaglutide: FDA-approved and prescription-only. AOD-9604: Not approved as a drug; permitted as a food additive in some jurisdictions. This is usually the most practical difference between two compounds, because it determines whether a supply chain is labelled and regulated at all.

Handling and storage

Semaglutide is stored refrigerate 2–8 °c; in-use pens may be kept at room temperature per label. AOD-9604 is stored refrigerate reconstituted vials; powder stable at room temperature briefly.

What Semaglutide and AOD-9604 have in common

Category: both listed as Metabolic

Each compound in brief

Semaglutide

Metabolic · Strong evidence

A long-acting GLP-1 receptor agonist with the strongest clinical weight-loss evidence of any peptide on the market.

Considerations: Muscle loss can account for a meaningful share of weight lost — resistance training and protein intake matter · GI side effects are dose-dependent; titrate slowly · Weight regain is common after stopping

AOD-9604

Metabolic · Limited evidence

A GH fragment marketed for fat loss without the blood-sugar effects of full growth hormone — though human trials have been underwhelming.

Considerations: Phase IIb trials failed to beat placebo for weight loss at 12 weeks · Popular in clinics despite weak efficacy data · Best viewed as adjunctive, not a primary fat-loss tool

Frequently asked questions

How does AOD-9604 differ from semaglutide?

Semaglutide is a GLP-1 receptor agonist with extensive clinical evidence. AOD-9604 is a GH fragment studied for effects on fat metabolism and does not have the same clinical evidence base.

Which has stronger evidence?

Semaglutide has substantially stronger clinical evidence. PeptideIndex rates semaglutide Strong and AOD-9604 Limited.

Is AOD-9604 an approved weight-loss medicine?

No. The PeptideIndex profile describes it as an unapproved compound and notes that phase IIb weight-loss trials did not outperform placebo at 12 weeks.